Medicare AdvantageCoverageMedium impact
Rheumatoid Arthritis: Biologic Markers and Pharmacologic Assessment - Medicare Advantage (Revised)
Humana·Rheumatology, Internal Medicine, Family Medicine·Medicare Advantage
Effective date
Oct 1, 2025
We identified it
Jun 24, 2026
Summary
Humana Medicare Advantage has revised its policy for rheumatoid arthritis biologic markers and pharmacologic assessment testing, establishing coverage criteria for molecular diagnostic tests and laboratory-developed tests used in RA diagnosis and treatment monitoring. The policy clarifies that coverage follows CMS Local Coverage Determinations and requires tests to meet analytical validity, clinical validity, and clinical utility standards.
Action Required
Before October 1, 2025: Billing team must review current RA-related molecular diagnostic test billing practices and ensure compliance with applicable CMS Local Coverage Determinations based on geographic jurisdiction. Verify that any RA biomarker tests (such as Vectra DA, PrismRA, Anser ADA/IFX) meet medical necessity criteria outlined in the relevant LCD/LCA for your MAC jurisdiction. Update prior authorization workflows if required by local MAC policies.